Form 4 for AQST Aquestive Therapeutics, Inc.
Accepted 2025-09-29 00:00:00 ET · period of report 2025-09-26 · accession 0001214659-25-014288 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-29 | 2025-09-26 | AQST | Barber Daniel | Pres, CEO, Dir | S - Sale | $6.03 | -91.3K | 923.4K | -9% | -$550.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-26 | S | D | 91,343 | $6.03 | 923,430 | D | — | — | (F1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4. (F2) The reported transaction involves sale transactions from $6.00 to $6.11 per share. The weighted average price per share was $6.0343. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price. |